<?xml version="1.0" encoding="UTF-8"?>
<AssessmentQuestionSet xmlns="http://soap.sforce.com/2006/04/metadata">
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_INITIATION_CRITERIA_Q5_R1</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_INITIATION_CRITERIA_Q3</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_INITIATION_CRITERIA_Q2_R2</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_DISEASE_OVERVIEW_Q1</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_DISEASE_OVERVIEW_Q2</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_DISEASE_OVERVIEW_Q3</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_DISEASE_OVERVIEW_Q4</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_DISEASE_OVERVIEW_Q5</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_DISEASE_OVERVIEW_Q6</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_INITIATION_CRITERIA_Q1</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_INITIATION_CRITERIA_Q1_R1</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_INITIATION_CRITERIA_Q2</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_INITIATION_CRITERIA_Q2_R1</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_INITIATION_CRITERIA_Q3_R1</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_INITIATION_CRITERIA_Q3_R2</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_INITIATION_CRITERIA_Q4</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_INITIATION_CRITERIA_Q4_R1</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_INITIATION_CRITERIA_Q4_R2</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_INITIATION_CRITERIA_Q5</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q1</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q1_R1</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q2</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q2_R1</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q3</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q4</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q5</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q6</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q6_R1</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q6_R2</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q7</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q8</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q8_R1</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q8_R2</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q9</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q10</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q10_R1</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q11</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q11_R1</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q12</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_RENEWAL_CRITERIA_Q12_R1</assessmentQuestionDeveloperNames>
    <assessmentQuestionDeveloperNames>XLHBurosumab_InitialRenewal_COVERAGE_CRITERIA_Q1</assessmentQuestionDeveloperNames>
    <developerName>XLHBurosumab_InitialRenewal_QS</developerName>
    <name>XLHBurosumab_InitialRenewal_QS</name>
</AssessmentQuestionSet>
